Search research articles
Contact Us
Filters
Showing results (11-20 of 105) with videos related to
Page
of 11
Sort By:
Current Drug Targets
|
March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
Erwin Dreesen, Ann Gils, Severine Vermeire
The American Journal of Gastroenterology
|
April 3, 2026
Response to Shen et al
Yannick Hoffert, Anthony Buisson, Erwin Dreesen
Gastroenterology
|
April 17, 2025
The Gravity of a Unique Subcutaneous Anti-IL23 Induction Regimen
Judith Wellens, Erwin Dreesen, Marc Ferrante
CPT: Pharmacometrics & Systems Pharmacology
|
May 29, 2025
A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling
My-Luong Vuong, Geert Verbeke, Erwin Dreesen
The Lancet. Gastroenterology & Hepatology
|
December 14, 2024
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis
Yannick Hoffert, Marc Ferrante, Bram Verstockt, et al.
Journal of Crohn'S & Colitis
|
August 28, 2025
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study
Zhigang Wang, Marc Ferrante, Séverine Vermeire, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 8, 2019
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire, Erwin Dreesen, Konstantinos Papamichael, et al.
Expert Review of Clinical Pharmacology
|
January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Intensive Care Medicine
|
March 18, 2022
The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis
Matthias Gijsen, Erwin Dreesen, Joost Wauters, et al.
Pharmaceutics
|
July 29, 2023
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
Yani Berckmans, Yannick Hoffert, Ann Vankerckhoven, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 105) with videos related to
Sort By:
Page
of 11
Current Drug Targets
|
March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
Erwin Dreesen, Ann Gils, Severine Vermeire
The American Journal of Gastroenterology
|
April 3, 2026
Response to Shen et al
Yannick Hoffert, Anthony Buisson, Erwin Dreesen
Gastroenterology
|
April 17, 2025
The Gravity of a Unique Subcutaneous Anti-IL23 Induction Regimen
Judith Wellens, Erwin Dreesen, Marc Ferrante
CPT: Pharmacometrics & Systems Pharmacology
|
May 29, 2025
A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling
My-Luong Vuong, Geert Verbeke, Erwin Dreesen
The Lancet. Gastroenterology & Hepatology
|
December 14, 2024
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis
Yannick Hoffert, Marc Ferrante, Bram Verstockt, et al.
Journal of Crohn'S & Colitis
|
August 28, 2025
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study
Zhigang Wang, Marc Ferrante, Séverine Vermeire, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 8, 2019
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire, Erwin Dreesen, Konstantinos Papamichael, et al.
Expert Review of Clinical Pharmacology
|
January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Intensive Care Medicine
|
March 18, 2022
The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis
Matthias Gijsen, Erwin Dreesen, Joost Wauters, et al.
Pharmaceutics
|
July 29, 2023
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
Yani Berckmans, Yannick Hoffert, Ann Vankerckhoven, et al.
Page
of 11